Article abstract


Nature Immunology 8, 1246 - 1254 (2007)
Published online: 30 September 2007 | doi:10.1038/ni1515

Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction

Daniel E Kaufmann1,7, Daniel G Kavanagh1,7, Florencia Pereyra1,2, John J Zaunders3, Elizabeth W Mackey1, Toshiyuki Miura1,4, Sarah Palmer5, Mark Brockman1,4, Almas Rathod1, Alicja Piechocka-Trocha1,4, Brett Baker1, Baogong Zhu6, Sylvie Le Gall1, Michael T Waring1,4, Ryan Ahern1, Kristin Moss1, Anthony D Kelleher3, John M Coffin5, Gordon J Freeman6, Eric S Rosenberg1 & Bruce D Walker1,4


In progressive viral infection, antiviral T cell function is impaired by poorly understood mechanisms. Here we report that the inhibitory immunoregulatory receptor CTLA-4 was selectively upregulated in human immunodeficiency virus (HIV)–specific CD4+ T cells but not CD8+ T cells in all categories of HIV-infected subjects evaluated, with the exception of rare people able to control viremia in the absence of antiretroviral therapy. CTLA-4 expression correlated positively with disease progression and negatively with the capacity of CD4+ T cells to produce interleukin 2 in response to viral antigen. Most HIV-specific CD4+ T cells coexpressed CTLA-4 and another inhibitory immunoregulatory receptor, PD-1. In vitro blockade of CTLA-4 augmented HIV-specific CD4+ T cell function. These data, indicating a reversible immunoregulatory pathway selectively associated with CD4+ T cell dysfunction, provide a potential target for immunotherapy in HIV-infected patients.

Top
  1. Partners AIDS Research Center, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02115, USA.
  2. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
  3. Centre for Immunology, St Vincent's Hospital, Darlinghurst, New South Wales 2010, Australia.
  4. Howard Hughes Medical Institute, Chevy Chase, Maryland 20185, USA.
  5. HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA.
  6. Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
  7. These authors contributed equally to this work.

Correspondence to: Daniel E Kaufmann1,7 e-mail: dkaufmann@partners.org

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Inhibitory receptors: whose side are they on?

Nature Immunology News and Views (01 Nov 2007)

Dangerous T-cell amnesia

Nature Medicine News and Views (01 May 1999)

See all 5 matches for News And Views

Extra navigation

Subscribe to Nature Immunology

Subscribe

Open Innovation Challenges

ADVERTISEMENT